Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis

Next Previous
Trial Profile

Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Acorda Therapeutics

Most Recent Events

  • 09 Nov 2015 Post-hoc subgroup analysis results published in the Clinical Therapeutics
  • 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
  • 13 Mar 2013 Subgroup analysis presented at the the 65th American Academy of Neurology Annual Meeting (AAN-2013), according to an Acorda Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top